Therapy Areas: Inflammatory Diseases
Immix Biopharma names new director
29 July 2021 - Immix Biopharma Inc, a US-based company involved in Tissue Specific Therapeutics for oncology and inflammation, announced on Wednesday that Jane Buchan, PhD is its new director.Dr Bucha...
Pulmatrix names new director
28 July 2021 - Pulmatrix Inc (NASDAQ: PULM), a clinical-stage biopharmaceutical company, announced on Tuesday that it has appointed Anand Varadan as its new director, effective 26 July 2021.Presently,...
MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
28 July 2021 - - Data from a comparative study conducted by Eurofins Discovery showing commonality between US-based clinical stage pharmaceutical company MyMD Pharmaceuticals, Inc's (NASDAQ:...
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
28 July 2021 - - US-based biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and US-based immunology focused drug development company Aristea Therapeutics, Inc. have forged a strateg...
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedule
27 July 2021 - - US-based biopharmaceutical company Iveric bio, Inc. (NASDAQ: ISEE) has completed patient enrollment of GATHER2, the company's second pivotal clinical trial of Zimura (a...
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
...
Related Headlines

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

Vedanta Biosciences Raises USD 68m In Series D Financing

Magellan Rx Management Teams with mPulse Mobile to Address Social Isolation and Loneliness During COVID-19

Octapharma wins FDA approval for Octagam 10% for dermatomyositis based on positive international, multi-centre ProDERM study

Direct awarded US FDA approval to commence a Phase I/II trial of ExoFlo for post-acute COVID-19 syndrome

FDA Approves Octapharma's Octagam 10% for Adult Dermatomyositis

Aldeyra Therapeutics Receives Orphan Drug Designation from the US Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma

Amneal wins FDA approval for generic ocular product TobraDex

RedHill Biopharma Ltd concludes treatment and follow-up of global phase 2/3 study in patients hospitalised with severe COVID-19 pneumonia

First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Amneal Receives Approval for Generic TobraDex

Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma

Theradiag generates revenues of EUR5.5m for six months ended 30 June 2021

UK's JCVI recommends vaccine for vulnerable children under 18 years

Celltrion Group's CT-P59 indicates strong neutralising effect against the rapidly spreading Delta variant plus other variants of concern